“Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities”
Article contribution by Elisa Dama (Vescovi’s Lab ) on International Journal of Cancer, published in 2022.
Comment by Roberta Torinesi ( Vai’s Lab - Orlandi’s Lab )
Oncology research represents one of the leading issues of the scientific world, due to the great variety of cancer types with different molecular mechanisms involved in their onset and progression still shrouded in mystery. High-grade serous ovarian carcinoma (HGSOC) is a highly aggressive and frequently fatal cancer, whose high biological and genetic heterogeneity makes it intractable. In the paper “Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities”, published on International Journal of Cancer last February, Elisa Dama and co-authors collected a set of samples from a single patient affected by HGSOC, including ovarian cancer stem cells (OCSC), and representing the different stages in tumor progression. A panel of molecular signatures relevant in HGSOC and OCSC biology was derived by DNA and RNA sequencing and was shown not only to have a prognostic and predictive value, but also to suggest that the PI3K signaling pathway could be used as a potential drug target in ovarian cancer stem cells.
Congratulations Elisa and colleagues for your contribution to this important topic!
Find out more at the following link: https://doi.org/10.1002/ijc.33983
Hashtags: #BtBsPhD e #TeCSBi #TeCSBispotlight #VescoviLab_BtBs #VaiLab_BtBs #OrlandiLab_BtBs